Biomarker screen improves accuracy of chemical genotoxicity testing

An international research team, led by Albert J.Fornance Jr., M.D., has developed an in vitro transcriptomic biomarker, named TGxDDI, used to test drug candidates and chemical compounds to predict if they cause DNA damage and potentially cancer in humans. The TGxDDI biomarker allows for researchers to distinguish between potentially carcinogenic chemicals and non-carcinogenic chemicals that are toxic. The TGxDDI biomarker is more accurate then existing genotoxicity assays and has the potential to reduces costs, time and animal tests.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *